Navigation Links
Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
Date:10/25/2007

MTD in NSCLC Identified; Phase 2 Study Planned

WESTMINSTER, Colo., Oct. 25 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that results from three PDX studies were presented as posters during the 2007 AACR-NCI-EORTC conference held October 22-26, 2007 in San Francisco, California. The posters described the effects of PDX (pralatrexate) in patients with non-small cell lung cancer (NSCLC), in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease, and in human cancer models in vivo and in vitro.

PDX in NSCLC (Phase 1)

The poster entitled "Phase 1 study of the antifolate pralatrexate when given with vitamin B12 and folic acid supplementation in patients with advanced non-small cell lung cancer (NSCLC)" presented results of this Phase 1 dose ranging study. In the study, a total of 22 patients with relapsed or refractory NSCLC were treated at doses of 150 to 325 mg/m2 of PDX. The maximum tolerated dose (MTD) was determined to be 270 mg/m2, which is twice that observed in a previous Phase 1 study in which PDX was administered without vitamin supplementation. Clinically significant radiologic responses were observed. Greater than 50% of patients (13/22) received two or more prior treatment regimens. Based on PDX clinical experience to date, the Company plans to initiate a randomized Phase 2 study of PDX in patients with NSCLC.

PDX in NHL (Phase 1/2)

The poster entitled "A Phase '2-1-2' Study of Two Different Doses and Schedules of Pralatrexate, A High Affinity Substrate for the Redu
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. The TripleMaster PCR System for three different amplifications
2. Cloning Based on Efficient Three-Fragment Assembly DNA Ligation
3. Three Micron TSK-GEL ODS-100V Columns for High Throughput LCMS
4. Three finalists named for UW-Madison CIO
5. Three state businesses receive technology grants
6. Leading cancer institute to install three TomoTherapy systems
7. Waukesha considers wireless bids from three firms
8. Computerworld top 100 includes three Wisconsin CIOs
9. 30 days to success: Three simple steps to create your own international startup
10. Three firms get state tech development grants
11. Three more Wisconsin firms to present at venture forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2008)...28 ExonHit Therapeutics ...scovery company, announces today,the availability...use models,of human disease. These SpliceArray(TM... their therapeutic target discovery and validation...ofiling analysis, we identify novel,transcripts c...
(Date:11/27/2008)... On Monday, December 1, ...pean/5:30 a.m. Pacific, members of,Cell Therapeut...t team will,host a conference call to discuss the...e, California to jointly market and develop Zevali...ay, December 1, 8:30 a.m. Eastern/2:30 p.m. Ce...
(Date:11/27/2008)...zerland, November 27 Helsinn Healt...s signed a partnering agreement with,Zealand Phar...ation of,ZP1846, a GLP-2 (glucagon-like peptide-2...treat chemotherapy-induced diarrhea (CID), a debil...ancer treatment with a range of,chemotherapies. ,...
(Date:11/26/2008)...wins increase 400% to $16 million in third quarter...nclude $1.9 million non-cash goodwill impairment c...FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENC...ch organization (CRO) conducting studies in over 3...aceutical and biotechnology companies, today annou...
Breaking Biology Technology:ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies 2ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies 3Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist 2Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist 3Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist 4Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist 5Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist 6Encorium Reports Third Quarter 2008 Financial Results 2Encorium Reports Third Quarter 2008 Financial Results 3Encorium Reports Third Quarter 2008 Financial Results 4Encorium Reports Third Quarter 2008 Financial Results 5Encorium Reports Third Quarter 2008 Financial Results 6Encorium Reports Third Quarter 2008 Financial Results 7Encorium Reports Third Quarter 2008 Financial Results 8Encorium Reports Third Quarter 2008 Financial Results 9
... in the Madison economy since 1906 will be moving ...rb in May. , ,According to Atlantic Business Chro...th. The announcement came as a surprise to many. ,...et the chance to try to work with [Rayovac], said ...ave Cieslewicz. Keeping local businesses is import...
...,With deregulation of the retail electric utility ..., it appears to be a time to return to regulated u...egislators should revisit the original text for th...nt for its future direction. As Wisconsins positio...2 in the Priorities section, In meeting energy dem...
...y job market these days is an exercise in faith. E...ng hope that things are truly turning around. , ,... out of work. More and more often, when we tell th... I saw that job (on Craigs List or ChicWIT or ...ursuing it. It looks like a no-win situation." , ...
...ference in San Francisco is still seeping out (eve...news made the Wall Street Journal), the overall se...sm. , ,Remember that there are at least 15 IPOs q...cted to be in the $150 million range) and the afte...nitored. The last time the IPO window was open in ...
Other Biology Technology:Rayovac to Relocate Headquarters 2Wisconsin Should Create, like Renewables, an Energy Efficient Portfolio 2Wisconsin Should Create, like Renewables, an Energy Efficient Portfolio 3Wisconsin Should Create, like Renewables, an Energy Efficient Portfolio 4Pity the Midwest Technology Sales Guy 2Pity the Midwest Technology Sales Guy 3Pity the Midwest Technology Sales Guy 4Pity the Midwest Technology Sales Guy 52003 Biotech Results 2
(Date:11/27/2008)...on genetic polymorphisms induce major differentiat...ion, according to a paper published November 28 in...rnational team of researchers, led by Karsten Suhr...ith metabolomics, identifying genetic variants in ...ting differences in metabolic capacity can affect ...
(Date:11/27/2008)...entists at St. Jude Children,s Research Hospital h...cancer cells of children with acute lymphoblastic ...ers a pathway to designing treatments for ALL rela...e most common childhood cancer, ALL affects thousa...hough more than 80 percent of ALL cases are cured,...
(Date:11/26/2008)... Wildlife Conservation Society, the Government of ...create a new national park to help protect the wor...rilla. , The park now forms part of an important...s River National Park, safeguarding an estimated 1...lationalong with other rare species. Trans-boundar...
(Date:11/26/2008)...er shapes societies, but it is a factor only just ..., The Norwegian professor, writer and film maker...en, argues that water has played a unique and fund... history. Speaking at a European Science Foundatio...proposed that social scientists and historians hav...
Breaking Biology News(10 mins):Study identifies genetic variants giving rise to differences in metabolism 2St. Jude identifies genomic causes of a certain type of leukemia relapse 2St. Jude identifies genomic causes of a certain type of leukemia relapse 3New national park protects world's rarest gorilla 2New national park protects world's rarest gorilla 3Using water to understand human society, from the industrial revolution to global trade 2Using water to understand human society, from the industrial revolution to global trade 3Study Shows Physician Judgment is Important in Reducing Rate of RSV Related Hospitalizations Among High Risk Infants 1965 1Study Shows Physician Judgment is Important in Reducing Rate of RSV Related Hospitalizations Among High Risk Infants 1965 2Study Shows Physician Judgment is Important in Reducing Rate of RSV Related Hospitalizations Among High Risk Infants 1965 3Federal Health Plan for Children Still Leaves Needs Unmet 18376 1Federal Health Plan for Children Still Leaves Needs Unmet 18376 2Autistic Kids More Likely to Have Parents With Mental Illness 18374 1Autistic Kids More Likely to Have Parents With Mental Illness 18374 2Major League Baseball Hall of Famer Don Sutton Helps Kidney Cancer Patients Stay In The Game 28TM 29 18372 1Major League Baseball Hall of Famer Don Sutton Helps Kidney Cancer Patients Stay In The Game 28TM 29 18372 2Major League Baseball Hall of Famer Don Sutton Helps Kidney Cancer Patients Stay In The Game 28TM 29 18372 3Major League Baseball Hall of Famer Don Sutton Helps Kidney Cancer Patients Stay In The Game 28TM 29 18372 4Major League Baseball Hall of Famer Don Sutton Helps Kidney Cancer Patients Stay In The Game 28TM 29 18372 5
... Environmental and genetic factors lead to neural ...1 in 20 of every spontaneous abortion. One cause o... neural tube to migrate to the middle of the devel...ue of Nature is the first to report on the molecul...correct local within the developing neural tube of...
... Trees, particularly those with deep roots, contri...sts thought, according to a new study by biologist...rnia, Berkeley. , While scientists studying global...tion in removing carbon dioxide from the atmospher... have assumed a simple model of plants sucking wat...
... Almost three metres of tightly-coiled DNA strands... strands unwind and unfold and then re-package int... what happens if this process becomes entangled? ,...ivision is the job of special enzymes called topoi...er than previously thought, says U of T research. ...
... The cell is understood to be highly organized, wi...olecular motors shuttling components around. Resea...d Urbana-Champaign campuses now offer the first im...tion and transport within the cell nucleus. , Gen...al region of the nucleus, while inactive genes are...
Other Biology News:Deep-rooted plants have much greater impact on climate than experts thought 2Deep-rooted plants have much greater impact on climate than experts thought 3Deep-rooted plants have much greater impact on climate than experts thought 4Researchers unravel DNA tangles and enzyme seamstresses 2Movement of chromosome in nucleus visualized 2Movement of chromosome in nucleus visualized 3
Attofluor cell chamber from Molecular Probes (Invitrogen)
Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]
ImmunoPure Plus Immobilized Protein G, , , , Support: Cross-linked 6%, beaded agarose , Capacity: > 20 mg human IgG/ml of gel
Mouse monoclonal antibody to FMN2 - formin 2
Biology Products: